Detalhe da pesquisa
1.
Corrigendum: Wild-type microglia do not reverse pathology in mouse models of Rett syndrome.
Nature
; 525(7570): 552, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26176914
2.
Wild-type microglia do not reverse pathology in mouse models of Rett syndrome.
Nature
; 521(7552): E1-4, 2015 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25993969
3.
TALEN-Mediated Gene Editing of HBG in Human Hematopoietic Stem Cells Leads to Therapeutic Fetal Hemoglobin Induction.
Mol Ther Methods Clin Dev
; 12: 175-183, 2019 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30705922
4.
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Blood
; 109(10): 4168-70, 2007 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17227830
5.
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
Blood
; 102(4): 1466-73, 2003 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12689934
6.
An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
Bioconjug Chem
; 13(1): 40-6, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-11792177
7.
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Bioconjug Chem
; 13(1): 47-58, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-11792178